Loading
A phase 1/2 trial of TQB2930, TQB3616, Fulvestrant, Capecitabine, Vinorelbine and Eribulin in advanced solid tumours, run by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., now recruiting.
A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer is a phase 1/2 interventional study registered as NCT06202261 by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., with 154 participants planned, started 2023-04-13 and due to reach its primary completion in 2026-12. Interventions recorded: TQB2930 for injection, Paclitaxel for injection (albumin-bound), TQB3616 capsule, Fulvestrant injection, Capecitabine tablets and Vinorelbine tartrate injection.
Shares TQB3616, Sino Biopharmaceutical (Chia Tai Tianqing), Fulvestrant, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares TQB2930, Sino Biopharmaceutical (Chia Tai Tianqing), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Vinorelbine, Eribulin, Capecitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Vinorelbine, Eribulin, Capecitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Vinorelbine, Eribulin, Capecitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares TQB2930, Sino Biopharmaceutical (Chia Tai Tianqing) and the tag pipeline.
Shares Sino Biopharmaceutical (Chia Tai Tianqing), Capecitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Eribulin, Capecitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.